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Abstract
Background: In Mexico, inappropriate prescription of drugs with potential interactions causing serious
risks to patient health has been little studied. Work in this area has focused mainly on hospitalized patients,
with only specific drug combinations analyzed; moreover, the studies have not produced conclusive
results. In the present study, we determined the frequency of potential drug-drug and drug-disease
interactions in prescriptions for ambulatory patients over 50 years of age, who used Mexican Institute of
Social Security (IMSS) family medicine clinics. In addition, we aimed to identify the associated factors for
these interactions.
Methods: We collected information on general patient characteristics, medical histories, and medication
(complete data). The study included 624 ambulatory patients over 50 years of age, with non-malignant pain
syndrome, who made ambulatory visits to two IMSS family medicine clinics in Mexico City. The patients
received 7-day prescriptions for non-opioid analgesics. The potential interactions were identified by using
the Thompson Micromedex program. Data were analyzed using descriptive, bivariate and multiple logistic
regression analyses.
Results:  The average number of prescribed drugs was 5.9 ± 2.5. About 80.0% of patients had
prescriptions implying one or more potential drug-drug interactions and 3.8% of patients were prescribed
drug combinations with interactions that should be avoided. Also, 64.0% of patients had prescriptions
implying one or more potential drug disease interactions. The factors significantly associated with having
one or more potential interactions included: taking 5 or more medicines (adjusted Odds Ratio (OR): 4.34,
95%CI: 2.76–6.83), patient age 60 years or older (adjusted OR: 1.66, 95% CI: 1.01–2.74) and suffering from
cardiovascular diseases (adjusted OR: 7.26, 95% CI: 4.61–11.44).
Conclusion: The high frequency of prescription of drugs with potential drug interactions showed in this
study suggests that it is common practice in primary care level. To lower the frequency of potential
interactions it could be necessary to make a careful selection of therapeutic alternatives, and in cases
without other options, patients should be continuously monitored to identify adverse events.
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Background
During the last decades in Mexico, as elsewhere, the pop-
ulation has aged, causing an increase in the level of
chronic degenerative diseases and a consequent incre-
ment in medication. Polypharmacy is now common, and
carries a high risk of drug-drug interactions and drug-dis-
ease interactions. These may cause adverse effects, or the
therapeutic effects of the combined medicines may
change, with serious consequences for health. In the
United States 25% of ambulatory patients taking drug
combinations were at risk for clinically important interac-
tions [1]. Furthermore, it has been reported that about
40% of hospitalized patients had at least one potential
drug-disease interaction [2]; a large study including
70,203 outpatient visits by patients aged 65 and older
found that 2.6% ofvisits with at least one prescription had
one or more of the 50 inappropriate drug-disease combi-
nations examined [3]. A European study of 1601 ambula-
tory elderly patients, taking an average of seven different
drugs, found that 46.0% were at risk for at least one clini-
cally important potential drug-drug interaction [4]. It has
been shown that inappropriate prescription combina-
tions increase with patient age, are more frequent in men,
rise in line with the Charlson co-morbidity index [5], and
increase as the number of prescribed drugs increases
[2,3,6-8]. It is possible that other risk factors for potential
interactions exist, and these should be identified to estab-
lish successful methods for improving prescription prac-
tices.
Adverse consequences of drug interactions have been
shown in various studies. Drug-drug interactions cause
4.8% of hospitalizations attributed to drugs in the elderly
[9-11]. In most cases they are erroneously interpreted as
patient deterioration because of illness, poor adherence to
prescribed treatment, or infection [12].
In Mexico, inappropriate prescription of drugs with
potential interactions causing serious risks to patient
health has been little studied. Work in this area has
focused mainly on hospitalized patients, with only spe-
cific drug combinations analyzed [13]; moreover, the
studies have not produced conclusive results [14,15].
In the present study, we sought to determine the fre-
quency of potential drug-drug and drug-disease interac-
tions in prescriptions of ambulatory patients over 50 years
of age, who attended to Mexican Institute of Social Secu-
rity (IMSS) family medicine clinics. In addition, we aimed
at identifying factors associated to them.
Methods
The present study is a secondary data analysis from the
Educational Strategy Study (ESS) involving both doctors
and patients over 50 years of age, focused on improving
utilization of non-opioid analgesics in primary care study
and carried out during 2006 in two large IMSS family
medicine clinics (FMC) located in Mexico City.
IMSS is the largest medical institution in Mexico that pro-
vides health care for more than 53 million of Mexicans.
The provision of services is divided into three levels,
where the Family Medicine Clinic is the primary care level.
IMSS FMC range from 2 to 40 examining rooms; the clin-
ics included in the study had 32 examining rooms, which
means 64 family doctors working in the morning and
evening shifts (32 in each);. These clinics were selected by
convenience and are similar in organization to the rest of
those that constitute IMSS primary care system. Cross-sec-
tional data from 624 ambulatory patients over 50 years of
age who made visits to 127 family doctors (96% of all
family doctors) were collected. On average, five patients
seen by each family doctor were included consecutively.
The patients studied suffered from non-malignant pain
syndrome and received prescriptions of non-opioid anal-
gesics for 7 days or more. The variables analyzed were gen-
eral characteristics of the patient (age, marital status,
literacy), medical history (number of chronic diseases,
number of medicines prescribed), and complete informa-
tion about all oral and injected drugs prescribed by the
doctors during the consultation (including occasional
drugs and those that were prescribed for regular use,
besides the prescription of non-opioid analgesics
described as inclusion criteria). All patients were person-
ally interviewed immediately after the visit and the infor-
mation from the electronic medical record and from the
electronic prescription was registered. Most of informa-
tion (diagnosis and prescriptions) was obtained through
personal interview and additional data were obtained
from the electronic medical charts and the electronic pre-
scriptions.
The International Classification of Disease, version 10
(ICD-10) [16], and the Anatomical Therapeutic Chemical
classification system [17] served to codify the data. To
look for potential interactions every combination of pre-
scribed drugs was analyzed by using the Thompson
Micromedex program [18]. Drug-drug interactions were
sorted by clinical relevance using the Classification Sys-
tem of the Department of Pharmacology, Hospital Hud-
dinge, Stockholm, Sweden [19]. In this classification, drug
interactions are rated A and B when they are not of clinical
importance (type A), or the effect of the interaction has
not yet been established (type B). One interaction of type
C can cause possible changes in the therapeutic effects, or
may cause adverse effects, but can be avoided adjusting
the individual drug doses. A potential drug-drug interac-
tion of type D indicates a potential for severe adverse
effects; individual dose adjustment is difficult in these
cases. For this paper, only drug-drug interactions of type CBMC Health Services Research 2007, 7:147 http://www.biomedcentral.com/1472-6963/7/147
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and D were detected and analyzed. Using the Zhan Clas-
sification all drug-disease interactions were classified as
being of low, moderate or high clinical significance [3].
The IMSS Ethics Committee approved the ESS (registra-
tion number: 2005-785-185).
Statistical analysis
All collected data regarding medications prescribed were
included in the analysis. The descriptive analysis included
absolute and relative frequencies of categorical variables.
A bivariate analysis to ascertain potential factors associ-
ated with drug-drug and drug-disease interaction was per-
formed using the chi-square test for categorical variables.
To evaluate the risk factors related to the presence of drug-
drug interactions in prescription mixes, a multiple logistic
regression analysis by using the backward stepwise
method was performed; the correlation terms and interac-
tions among selected variables were also explored, and
goodness of fit test was assessed for the best model. Vari-
ables that were explored in the bivariate analysis were:
gender (female), marital status (single), age (≥ 60 years of
age), literacy (only elementary school o less), number of
chronic conditions, diagnosis (cardiovascular, gastroin-
testinal, endocrine, genital and urinary, neurological,
mental, infection disease, as well as musculoskeletal and
joint disorders), and number of drugs prescribed (≥ 5).
Only statistically significant associations and plausible
variables were considered for the logistic regression
model.
All P-values were obtained from two-tailed tests and the
significance level selected was P  = 0.05. The programs
SPSS 10.0 for Windows (SPSS Inc, Chicago, IL), and the
statistics package of STATA Corporation (College Station,
TX) were used to analyze data.
Results
The median age of patients was 69 years (range 50–94
years). Most (78.7%) were women, 63.9% were house-
wives and more than half were single, divorced or wid-
owed. The average number of chronic diseases per patient
was 3.4 ± 1.5 and the most frequent illnesses were degen-
erative joint disease, hypertension, chronic gastritis, dia-
betes mellitus and dyslipidemia (Table 1). The total
number of medicines prescribed to the 624 patients was
3,739 with an average of 5.9 ± 2.5 drugs per patient. The
most frequent drugs prescribed were active on the alimen-
tary tract, or affected general metabolism (drugs combat-
ing gastrointestinal diseases were the most commonly
prescribed drugs). The next most common class of drugs
was active on the cardiovascular system; drugs addressing
muscle-skeletal system problems were next in prescription
frequency, and, finally, drugs active on the nervous sys-
Table 1: General patient characteristics and medical history









Unskilled worker 38 (6.0)
Clerk 48 (7.7)
Professionals 4 (0.6)
Age, years, Median (range) 69 (50–94)
Education, years, Median (range) 6 (0–22)
Medical History
Cardiovascular disease 446 (71.5)
Myocardial 123 (19.7)
Hypertension 420 (67.3)
Peripheral vascular 64 (10.3)
Pulmonary disease 39 (6.3)
Gastrointestinal disease 253 (40.5)
Chronic Gastro-duodenitis/ulcer disease 225 (36.1)
Others: inflammatory bowel, liver disease etc. 49 (7.9)
Genito-urinary disease 47 (7.5)
Renal disease with renal insufficiency 40 (6.4)
Prostate disease 7 (1.1)
Musculoskeletal and joint disorders 597 (95.7)
Osteoarthritis 565 (90.5)
Rheumatoid arthritis 16 (2.6)
Gout 11 (1.8)
Endocrine, alimentary and metabolic disease 313 (50.2)
Diabetes mellitus 184 (29.5)
Thyroid gland disease 22 (3.5)
Hyperlipidemia 155 (24.8)
Obesity 39 (6.3)
Neurological disease 51 (8.2)
Mental disease 33 (5.2)
Hematological disease 17 (2.7)
Ophthalmological disease 26 (4.2)
Dermatological disease 14 (2.3)
Infections and parasitic disease 118 (18.9)
Respiratory infections 47 (7.5)
Gastrointestinal infections 6 (1.0)




Disease number 3.6 ± 1.5
Chronic disease 3.4 ± 1.5
Acute disease and trauma 0.2 ± 0.4
*SD: Standard deviationBMC Health Services Research 2007, 7:147 http://www.biomedcentral.com/1472-6963/7/147
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tem. In this final group paracetamol was the main drug
consumed (Table 2).
About 80% of patients had prescriptions for one or more
combinations in the potential drug-drug interaction class.
The most frequent drug interactions were type C, such as
combinations of non-steroidal anti-inflammatory drugs
(NSAIDs) with antihypertensive drugs (40.4%), and with
low doses of acetylsalicylic acid (ASA) (34.0%). 3.8% of
patients were prescribed drug combinations with interac-
tions that should be avoided, and two patients were pre-
scribed drugs with two potential type D interactions. Also,
400 patients (64.0%) had one or more potential drug-dis-
ease interactions of moderate clinical significance, given
that the medicines prescribed could cause either light or
moderate adverse effects. The most frequent were NSAIDs
in patients with hypertension and/or chronic heart failure;
β-blocking agents in patients with diabetes mellitus, and
NSAIDs in patients with chronic renal failure (Table 3)
When analyzing both classes of potential interactions we
did not find statistically significant differences in patient
gender, marital status or education.
Table 4 shows bivariate analysis of the relationship
between the characteristics of patient and prescription,
and potential drug-drug interactions. The variables found
significant (p < 0.05) were, patient older than sixty years,
3 or more diseases, cardiovascular disease, endocrine, ali-
mentary and metabolic disease and receiving five or more
medicines.
The factors significantly associated with having one or
more potential drug-drug interactions in the logistic
regression model included: taking five or more medicines
(adjusted odds ratio (aOR): 4.34, 95%CI: 2.76–6.83),
patient age of 60 years or older (aOR: 1.66, 95% CI: 1.01–
2.74) and suffering from cardiovascular diseases (aOR:
7.26, 95% CI: 4.61–11.44) (Table 5); the adjustment var-
iables were: number of disease ≥ 3 and endocrine, alimen-
tary and metabolic disease.
The bivariate analysis of the factors associated with drug-
disease interaction did not show any statistically signifi-
cant association; therefore, a logistic regression analysis
was not performed for these interactions.
Table 2: Prescribed drugs






Alimentary tract and metabolism 990 (26.5) 495 (79.3)
Drugs used in diabetes 250 (6.7) 179 (28.7)
Drugs for gastrointestinal disease** 437 (11.7) 332 (53.2)
Vitamins 236 (6.3) 209 (33.5)
Mineral supplements 88 (2.4) 87 (13.9)
Blood and blood forming organs 253 (6.8) 247 (39.6)
Cardiovascular system 929 (24.8) 470 (75.3)
Dermatologicals 81 (2.1) 66 (10.6)
Genitourinary system and sex hormones 20 (0.5) 20 (3.2)
Systemic hormonal preparations 29 (0.8) 27 (4.3)
Antiinfectives for systemic use 158 (4.2) 149 (23.9)
Musculoskeletal system 680 (18.2) 569 (91.2)
Non-steroidal anti-inflammatory drugs 611 (16.3) 560 (89.8)
Others drugs for the musculoskeletal system 69 (1.8) 61 (9.8)
Nervous system 380 (10.2) 298 (47.8)
Analgesics and antipyretics (Paracetamol) 229 (36.7) 229 (36.7)
Other nervous system drugs*** 152 (4.1) 119 (19.1)
Respiratory system 117 (3.1) 81 (13.0)
Sensory organs 102 (2.7) 56 (9.0)
Mean number of prescribed drugs, Mean ± SD**** 5.9 ± 2.5




≥ 7 224 (35.9)
*Anatomical Therapeutic Chemical classification system (ATC)
**A02–A09 in the ATC
***N01; N02A and C; N03–N07 in the ATC
****SD: Standard deviationBMC Health Services Research 2007, 7:147 http://www.biomedcentral.com/1472-6963/7/147
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Discussion
Various studies have shown that potential drug-drug and
drug disease interactions are frequent when patients
receive multiple prescriptions. This is true for both ambu-
latory and hospitalized patients, and, in many cases,
causes adverse effects and changes in therapeutic efficacies
of the combined medicines, with consequent poor con-
trol of the diseases under treatment [1-4,6-12].
In the present study, we found that the frequency of
potential drug-drug interactions in prescriptions of family
doctors working in primary care clinics in Mexico City was




Potential drug-drug interactions 492 (78.8)




≥ 5 92 (14.7)
Type D 24 (3.8)
ACE* inhibitors + potassium-sparing diuretics (or potassium supplementation) 11 (1.8)
NSAID*+ Methotrexate 5 (0.8)
NSAID* +anticoagulants (or glucocorticoids) 5 (0.8)
β blocking agents + Verapamil (or Fluoxetin) 3 (0.4)
Type C 468 (75.0)
ACE* inhibitors + NSAID* 252 (40.4)
NSAID*+ low dose ASA* 212 (34.0)
NSAID*+ sulfonylureas 128 (20.5)
ACE* inhibitors + low dose ASA* 130 (20.8)
β blocking agents + NSAID* 107 (17.1)
NSAID* + Diuretics 105 (16.8)
ACE* inhibitors + glybenclamide 68 (10.9)
NSAID*+ other NSAID* 51 (8.2)
ACE* inhibitors + thiazide diuretics 47 (7.6)
Pravastatin + bezafibrate 35 (5.6)
Pentoxiyilline + antihypertensives 37 (5.9)
Metformin+ ranitidine 40 (6.5)
Glibenclamide + antimycotics or cotrimoxazole 24 (3.9)
Furosemide + ACE* inhibitors 21 (3.4)
ACE* inhibitors + antiacids 19 (3.1)
Alendronate + NSAIDs* 18 (2.9)
Insulin + antihypertensive 18 (2.9)
Pentoxifylline + hypoglycemic agents 14 (2.2)
Acetaminophen + carbamazepin 14 (2.2)
Ranitidine + azole type of antimycotics 11 (1.8)
Others 61 (9.4)
Potential drug-disease interactions 400 (64.1)
Number of potential drug-disease interactions
1 346 (55.4)
≥ 2 54 (8.7)
NSAIDs* in patients with hypertension and/or chronic heart failure 384 (61.5)
β blocking agents in patients with diabetes mellitus 31 (5.0)
NSAIDs* in patients with chronic renal insufficiency 18 (2.9)
NSAIDs* in patients with previous peptic ulcer 8 (1.3)
Thiazides diuretics in patients with gout 7 (1.1)
Metformin in patients with chronic renal insufficiency or congestive heart failure 6 (1.0)
β blocking agents in patients with peripheral vascular disease 4 (0.6)
β blocking agents in patients with asthma/COPD* 3 (0.5)
Others 5 (1.0)
*ACE: angiotensin-converting enzyme; ASA: acetylsalicylic acid; COPD: chronic obstructive pulmonary disease; NSAID: Non-steroidal anti-
inflammatory drugs.BMC Health Services Research 2007, 7:147 http://www.biomedcentral.com/1472-6963/7/147
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almost 80.0%; this is higher than the frequency in Europe
[4] (46.0%) and in the United States [1] (25.0%) in
ambulatory patients over 59 years of age. The rates we
found may be unique for the sample and may not be fully
representative of Mexican population situation. The
higher prevalence of potential drug-drug and drug-disease
interactions in this study compared to others studies is
likely attributable to the characteristics of the study sam-
ple (older adults with very high prevalence – nearly 90.0%
– of NSAID utilization) among other reasons.
The frequency of type D interactions (which should be
avoided) was smaller (3.8%) in our work, when com-
pared with other studies (the type D frequency was 10.0%
in the European study) [4]. The three combinations with
drug-drug potential interactions that were found most fre-
quently in our work are among those reported by Bjork-
man [4]. These drug interactions are of type C and,
without dose adjustment and patient monitoring, such
interactions may antagonize drug effects on vascular tone
and may result in increases in blood pressure (angi-
otensin-converting enzyme (ACE) inhibitors + NSAIDs,
ACE inhibitors + low doses of ASA) [20] or may increase
gastrointestinal adverse effects (NSAIDs + low doses of
ASA) [21]. These finding coincide with the literature
review performed by Becker et al., in which it was reported
that drugs most often responsible for hospital admissions
were NSAIDs and cardiovascular drugs, and the most
common causes for such admissions were gastrointestinal
tract bleeding and hyper- or hypotension [11].
Other authors have reported that both types C and D
show similar hospitalization frequencies [10]. Therefore,
medical doctors must be familiar with both interaction
types.
We found that not only potential drug-drug, but also
drug-disease interactions, were frequent in prescriptions.
The frequency of the latter (64.0%) found in the present
work is greater than reported in either hospitalized
patients [2] or ambulatory patients [3].
The most frequent were interactions involving NSAIDs
that were prescribed to patients with hypertension and/or
chronic heart failure, and prescriptions of NSAIDs and
ACE inhibitors. Although this finding was influenced by
patient inclusion criteria, it shows that the flaws in the
knowledge of prescribers regarding interactions of this
Table 5: Factors related to the potential drug-drug interactions
Variables Odds ratio 95% Confidence intervals Adjusted Odds Ratio 95% Confidence intervals
Patient age ≥ 60 2.44* 1.59 – 3.75 1.66* 1.01 – 2.74
Cardiovascular disease 9.37* 6.09 – 14.41 7.26* 4.61 – 11.44
Number of medicines ≥ 5 5.76* 3.82 – 8.69 4.34* 2.76 – 6.83
Adjustment variables: number of disease ≥ 3 and endocrine, alimentary and metabolic disease. 
Goodness of fit > 0.05
*P < 0.05
Table 4: Relationship between patient's and prescription's characteristics and potential drug-drug interactions
Variables Patients without potential drug-drug 
interactions in their prescription
n = 132
Patients with at least one potential drug-
drug interactions in their prescription
n = 492
Gender (female) 105 (79.5) 386 (78.5)
Civil status (single) 61 (46.2) 259 (52.6)
Did not work 102 (77.3) 416 (84.6)
Literacy (only elementary school o less) 67 (54.9) 266 (62.9)
Patient age ≥ 60* 87 (65.9) 406 (82.5)
Number of disease ≥ 3* 73 (55.3) 396 (80.5)
Cardiovascular disease* 43 (32.6) 403 (81.9)
Musculoskeletal and joint disorders 126 (95.5) 471(95.7)
Gastrointestinal disease 48 (36.4) 205 (41.7)
Endocrine, alimentary and metabolic disease* 38 (28.8) 275 (55.9)
Pulmonary disease 8 (6.0) 31 (6.3)
Mental disease 12 (9.1) 21 (4.3)
Neurological disease 11 (8.3) 40 (8.1)
Infections and parasitic disease 30 (22.7) 88 (17.9)
Number of medicines ≥ 5* 50 (37.9) 383 (77.8)
*p < 0.05BMC Health Services Research 2007, 7:147 http://www.biomedcentral.com/1472-6963/7/147
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group of drugs. In such cases, other therapeutic options
should be considered to avoid potential drug interactions,
like using paracetamol to manage osteoarthritis in
patients with hypertension being treated with ACE inhib-
itors.
In general, our findings agree with other studies reporting
that the risk of potential drug-drug interactions increases
with each new prescription issued and with the aging of
the patient [2,3,6-8]. In line with this, we found that
patient age of 60 years or older and taking 5 or more med-
icines increases the risk of such potential interactions.
Polypharmacy is an important problem in older people
that has been reported as a frequent event all over the
world [3,4,22,23]. In our sample, the patients took an
average of 5.9 drugs, and those 60 years or older took an
average of 6.1 drugs (37.3% of them took 7 or more med-
icines).
Within the context of this study, there exists limited pub-
lished local information regarding the average number of
drugs that a patient older than fifty years gets prescribed.
Previous studies have been carried out in specific groups
of older patients, such as community-dwelling elderly
hospitalized due to inappropriate drug prescriptions [24],
in nursing home residents [25] and in patients with
hypertension [26]. For example, in hospitalized elderly
patients, the average number of drugs consumed was 6.0
[24], and in nursing home residents was 2.8 [25], and in
the study addressing patients with hypertension [26] aged
60 years and older, only 1.9% were taking three or more
hypertensive drugs; yet, in this study the consumption of
other drugs was not analyzed. Further studies should be
advisable to gain in depth knowledge about the average
number of drugs that family doctors prescribe to the eld-
erly in Mexico.
Furthermore, we found that having a cardiovascular dis-
ease increases seven-fold the risk of potential drug-disease
interactions. This means, as has been recommended in
prior studies from other countries, that doctors need to
pay more attention to drug prescription and patient mon-
itoring when treating older individuals [2,3,6,7] also, the
patients with cardiovascular diseases deserve more atten-
tion. It is necessary to consider interventions to reduce the
drug interaction problem. Computer-based access to
information on all prescriptions dispensed, and auto-
mated doctor alerts on the most frequent potential drug
interactions encountered, would be most helpful. These
tools are effective in reducing inappropriate prescriptions,
and doctor acceptance in other populations has been
reported [27,28]. Alternatives such as programs of contin-
uous medical education, or pharmaceutical support, may
also be considered. It has been found, however, that even
pharmacists cannot detect all potential drug interactions
because their number rises dramatically as the number of
medicines prescribed increases [29].
Among the limitations of this study is that it only permits
an approximation to problem of drug interactions in fam-
ily medicine practice. The patients' group studied was very
limited (all patients had non-malignant pain syndrome).
We believe that some drug interactions may be more fre-
quent in such patients. For example, we found that the
most frequent potential drug-disease interaction involved
the use of NSAIDs in patients with hypertension. In
patients with acute or infectious disease is possible that
other interactions would be found more frequently. Also,
in this cross-sectional study we did not determine any
possible relationship between drug-drug nor drug-disease
interactions and the health status of the population stud-
ied.
It is possible to conclude that the high frequency of pre-
scription of drugs with potential drug interactions is com-
mon in primary care level; the easiest way to reduce the
frequency of them is to decrease the number of medicines
prescribed. Nevertheless, sometimes it is difficult to
reduce the number of drugs prescribed for patients with
multiple chronic conditions; therefore, to lower the fre-
quency of potential interactions it could be necessary to
make a careful selection of therapeutic alternatives, and in
cases without other options, patients should be continu-
ously monitored to identify adverse events.
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